Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 77

Similar articles for PubMed (Select 22914469)

1.

A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010.

Sprague BL, Trentham-Dietz A, Cronin KA.

Obstet Gynecol. 2012 Sep;120(3):595-603. doi: 10.1097/AOG.0b013e318265df42.

2.

Trends of postmenopausal estrogen plus progestin prevalence in the United States between 1970 and 2010.

Jewett PI, Gangnon RE, Trentham-Dietz A, Sprague BL.

Obstet Gynecol. 2014 Oct;124(4):727-33. doi: 10.1097/AOG.0000000000000469.

PMID:
25198271
3.
4.

Changes in U.S. prescribing patterns of menopausal hormone therapy, 2001-2003.

Hing E, Brett KM.

Obstet Gynecol. 2006 Jul;108(1):33-40.

PMID:
16816053
5.

Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results.

Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K.

Ann Intern Med. 2004 Feb 3;140(3):184-8.

PMID:
14757616
6.

Changes of menopausal hormone therapy use pattern since 2000: results of the Berlin Spandau Longitudinal Health Study.

Du Y, Scheidt-Nave C, Schaffrath Rosario A, Ellert U, Dören M, Knopf H.

Climacteric. 2009 Aug;12(4):329-40. doi: 10.1080/13697130902745120.

PMID:
19437194
7.

National use of postmenopausal hormone therapy: annual trends and response to recent evidence.

Hersh AL, Stefanick ML, Stafford RS.

JAMA. 2004 Jan 7;291(1):47-53.

PMID:
14709575
8.

Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women.

Lacey JV Jr, Brinton LA, Lubin JH, Sherman ME, Schatzkin A, Schairer C.

Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1724-31.

9.

After the Women's Health Initiative: decision making and trust of women taking hormone therapy.

Schonberg MA, Davis RB, Wee CC.

Womens Health Issues. 2005 Jul-Aug;15(4):187-95.

PMID:
16051110
10.

Changes in women's use of hormones after the Women's Health Initiative estrogen and progestin trial by race, education, and income.

Wei F, Miglioretti DL, Connelly MT, Andrade SE, Newton KM, Hartsfield CL, Chan KA, Buist DS.

J Natl Cancer Inst Monogr. 2005;(35):106-12.

PMID:
16287895
11.

Effects of postmenopausal hormone therapy on incident atrial fibrillation: the Women's Health Initiative randomized controlled trials.

Perez MV, Wang PJ, Larson JC, Virnig BA, Cochrane B, Curb JD, Klein L, Manson JE, Martin LW, Robinson J, Wassertheil-Smoller S, Stefanick ML.

Circ Arrhythm Electrophysiol. 2012 Dec;5(6):1108-16. doi: 10.1161/CIRCEP.112.972224. Epub 2012 Nov 20.

12.

Prevalence of estrogen or estrogen-progestin hormone therapy use.

Brett KM, Reuben CA.

Obstet Gynecol. 2003 Dec;102(6):1240-9.

PMID:
14662210
13.
14.

Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.

McTiernan A, Martin CF, Peck JD, Aragaki AK, Chlebowski RT, Pisano ED, Wang CY, Brunner RL, Johnson KC, Manson JE, Lewis CE, Kotchen JM, Hulka BS; Women's Health Initiative Mammogram Density Study Investigators.

J Natl Cancer Inst. 2005 Sep 21;97(18):1366-76.

15.

Correlates of postmenopausal estrogen use and trends through the 1980s in two southeastern New England communities.

Derby CA, Hume AL, Barbour MM, McPhillips JB, Lasater TM, Carleton RA.

Am J Epidemiol. 1993 May 15;137(10):1125-35.

PMID:
8317442
16.

Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health Study cohort.

Lacey JV Jr, Leitzmann MF, Chang SC, Mouw T, Hollenbeck AR, Schatzkin A, Brinton LA.

Cancer. 2007 Apr 1;109(7):1303-11. Erratum in: Cancer. 2007 Aug 15;110(4):937.

17.

Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort.

Lacey JV Jr, Brinton LA, Leitzmann MF, Mouw T, Hollenbeck A, Schatzkin A, Hartge P.

J Natl Cancer Inst. 2006 Oct 4;98(19):1397-405.

18.

Continued decline in blood lead levels among adults in the United States: the National Health and Nutrition Examination Surveys.

Muntner P, Menke A, DeSalvo KB, Rabito FA, Batuman V.

Arch Intern Med. 2005 Oct 10;165(18):2155-61.

PMID:
16217007
19.

Transdermal hormone therapy and the risk of stroke and venous thrombosis.

Speroff L.

Climacteric. 2010 Oct;13(5):429-32. doi: 10.3109/13697137.2010.507111.

PMID:
20670199
20.

A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the Women's Health Initiative.

Steinkellner AR, Denison SE, Eldridge SL, Lenzi LL, Chen W, Bowlin SJ.

Menopause. 2012 Jun;19(6):616-21. doi: 10.1097/gme.0b013e31824bb039.

PMID:
22648302
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk